Dysfunctional dopaminergic neurotransmission in asocial BTBR mice

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Squillace, M ^a,b   Dodero, L ^b   Federici, M ^c,d   Migliarini, S ^e   Errico, F ^a,f   Napolitano, F ^a,f   Krashia, P ^c   Di Maio, A ^a   Galbusera, A ^b   Bifone, A ^b   Scattoni, M L ^g   Pasqualetti, M ^e   Mercuri, N B ^c,d   Usiello, A ^a,h   Gozzi, A ^b  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^h SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; VANOXERINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 2 RECEPTOR; GLUTAMATE RECEPTOR 1; HALOPERIDOL; MESSENGER RNA; QUINPIROLE; SERINE 845; SERINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTISM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; FOREBRAIN; FUNCTIONAL MAGNETIC RESONANCE IMAGING; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOTOR ACTIVITY; MOUSE; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; REWARD; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; STEREOTYPY; ANIMAL MODEL; ANTISOCIAL BEHAVIOR; BEHAVIOR; BRAIN FUNCTION; COMPULSION; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; FUNCTIONAL NEUROIMAGING; HALOPERIDOL-INDUCED CATALEPSY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOCOMOTION; MEDIAL PREFRONTAL CORTEX; NERVE STIMULATION; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SOMATOSENSORY CORTEX; SYNAPTIC TRANSMISSION; TREATMENT RESPONSE; UPREGULATION;

EID: 84907348224     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.69     Document Type: Article

References (98)

1. Chugani DC. Neuroimaging and neurochemistry of-autism. Pediatr Clin North Am 2012; 59: 63-73.
2. Rinaldi A, Mandillo S, Oliverio A, Mele A. D1 and D2 receptor antagonist injections in the prefrontal cortex selectively impair spatial learning in mice. Neuropsychopharmacology 2007; 32: 309-319. (Pubitemid 46106938)
3. Pezze MA, Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 2004; 74: 301-320. (Pubitemid 39586721)
4. Hill EL. Executive dysfunction in autism. Trends Cogn Sci 2004; 8: 26-32. (Pubitemid 38028515)
5. Gaigg SB, Bowler DM. Differential fear conditioning in Asperger's syndrome: Implications for an amygdala theory of autism. Neuropsychologia 2007; 45: 2125-2134. (Pubitemid 46654107)
6. Coldren JT, Halloran C. Spatial reversal as a measure of executive functioning in children with autism. J Genet Psychol 2003; 164: 29-41. (Pubitemid 37177468)
7. Schultz RT. Developmental deficits in social perception in autism: the role of the amygdala and fusiform face area. Int J Dev Neurosci 2005; 23: 125-141. (Pubitemid 40313547)
8. Dawson G, Webb SJ, Wijsman E, Schellenberg G, Estes A, Munson J et al. Neurocognitive and electrophysiological evidence of altered face processing in parents of children with autism: implications for a model of abnormal development of social brain circuitry in autism. Dev Psychopathol 2005; 17: 679-697.
9. Solomon M, Smith AC, Frank MJ, Ly S, Carter CS. Probabilistic reinforcement learning in adults with autism spectrum disorders. Autism Res 2011; 4: 109-120.
10. Zalla T, Sav AM, Leboyer M. Stimulus-reward association and reversal learning in individuals with asperger syndrome. Res Autism Spect Disord 2009; 3: 913-923.
11. Kohls G, Schulte-Ruther M, Nehrkorn B, Muller K, Fink GR, Kamp-Becker I et al. Reward system dysfunction in autism spectrum disorders. Soc Cogn Affect Neurosci 2012; 8: 565-572.
12. Dichter GS, Felder JN, Green SR, Rittenberg AM, Sasson NJ, Bodfish JW. Reward circuitry function in autism spectrum disorders. Soc Cogn Affect Neurosci 2012; 7: 160-172.
13. Scott-Van Zeeland AA, Dapretto M, Ghahremani DG, Poldrack RA, Bookheimer SY. Reward processing in autism. Autism Res 2010; 3: 53-67.
14. Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C et al. De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry 2013; 18: 1315-1323.
15. Hettinger J, Liu X, Hudson M, Lee A, Cohen I, Michaelis R et al. DRD2 and PPP1R1B (DARPP-32) polymorphisms independently confer increased risk for autism spectrum disorders and additively predict affected status in male-only affected sib-pair families. Behav Brain Funct 2012; 8: 19.
16. Reiersen AM, Todorov AA. Association between DRD4 genotype and autistic symptoms in DSM-IV ADHD. J Canadian Acad Child Adolesc Psychiatry 2011; 20: 15-21.
17. Nguyen M, Roth A, Kyzar EJ, Poudel MK, Wong K, Stewart AM et al. Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD). Neurochem Int 2014; 66: 15-26.
18. Kohls G, Chevallier C, Troiani V, Schultz RT. Social 'wanting' dysfunction in autism: neurobiological underpinnings and treatment implications. J Neurodev Disord 2012; 4: 10.
19. Bourgeron T. A synaptic trek to autism. Curr Opin Neurobiol 2009; 19: 231-234.
20. Yang M, Abrams DN, Zhang JY, Weber MD, Katz AM, Clarke AM et al. Low sociability in BTBR T+tf/J mice is independent of partner strain. Physiol Behav 2012; 107: 649-662.
21. Silverman JL, Tolu SS, Barkan CL, Crawley JN. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 2010; 35: 976-989.
22. Scattoni ML, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in adult BTBR T+tf/J mice during three types of social encounters. Genes Brain Behav 2011; 10: 44-56.
23. McFarlane HG, Kusek GK, Yang M, Phoenix JL, Bolivar VJ, Crawley JN. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behav 2008; 7: 152-163. (Pubitemid 351342192)
24. Ferrari L, Turrini G, Crestan V, Bertani S, Cristofori P, Bifone A et al. A robust experimental protocol for pharmacological fMRI in rats and mice. J Neurosci Methods 2012; 204: 9-18.
25. Sforazzini F, Schwarz AJ, Galbusera A, Bifone A, Gozzi A. Distributed BOLD and CBV-weighted resting-state networks in the mouse brain. Neuroimage 2013; 15: 403-415.
26. Gozzi A, Apar J, Giovanelli A, Bertollini C, Crestan V, Schwarz AJ et al. A neural switch for active and passive fear. Neuron 2010; 67: 656-666.
27. Dodero L, Damiano M, Galbusera A, Bifone A, Tsaftsaris SA, Scattoni ML et al. Neuroimaging evidence of major morpho-anatomical and functional abnormalities in the BTBR T+TF/J mouse model of autism. PLoS One 2013; 8: e76655.
28. Yang BZ, Paolicelli R, Sforazzini F, Weinhard L, Bolasco G, Pagani F et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 2013; 17: 400-406.
29. Young J, Goey A, Minassian A, Perry W, Paulus M, Geyer M. GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology 2010; 208: 443-454.
30. Gozzi A, Schwarz AJ, Reese T, Crestan V, Bifone A. Drug-anaesthetic interaction in phMRI: the case of the pyschotomimetic agent phencyclidine. Magn Reson Imag 2008; 26: 999-1006.
31. Schwarz AJ, Reese T, Gozzi A, Bifone A. Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course. Magn Reson Imaging 2003; 21: 1191-1200. (Pubitemid 38199724)
32. Geracitano R, Paolucci E, Prisco S, Guatteo E, Zona C, Longone P et al. Altered long-term corticostriatal synaptic plasticity in transgenic mice overexpressing human Cu/Zn superoxide dismutase mutation. Neuroscience 2003; 118: 399-408. (Pubitemid 36423255)
33. Napolitano F, Bonito-Oliva A, Federici M, Carta M, Errico F, Magara S et al. Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine. J Neurosci 2010; 30: 11043-11056.
34. Errico F, Santini E, Migliarini S, Borgkvist A, Centonze D, Nasti V et al. The GTPbinding protein Rhes modulates dopamine signalling in striatal medium spiny neurons. Mol Cell Neurosci 2008; 37: 335-345. (Pubitemid 351173853)
35. Santini E, Heiman M, Greengard P, Valjent E, Fisone G. Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal 2009; 2: ra36.
36. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB et al. Regulation of the phosphorylation of the dopamine-and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA 2000; 97: 1856-1860. (Pubitemid 30118533)
37. Migliarini S, Pacini G, Pelosi B, Lunardi G, Pasqualetti M. Lack of brain serotonin affects postnatal development and serotonergic neuronal circuitry formation. Mol Psychiatry 2013; 18: 1106-1118.
38. Ren J, Xu H, Choi JK, Jenkins BG, Chen YI. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses. Synapse 2009; 63: 764-772.
39. Gozzi A, Tessari M, Dacome L, Agosta F, Lepore S, Lanzoni A et al. Neuroimaging evidence of altered fronto-cortical and striatal function after prolonged cocaine self-administration in the rat. Neuropsychopharmacology 2011; 36: 2431-2440.
40. Knutson B, Gibbs S. Linking nucleus accumbens dopamine and blood oxygenation. Psychopharmacology 2007; 191: 813-822. (Pubitemid 46355904)
41. Gozzi A, Lepore S, Vicentini E, Merlo-Pich E, Bifone A. Differential effect of Orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor yohimbine. Neuropsychopharmacology 2013; 38: 2120-2130.
42. Gozzi A, Massagrande M, Amantini D, Antolini M, Martinelli P, Cesari N et al. Functional magnetic resonance imaging reveals different neural substrates for the effects of Orexin-1 and Orexin-2 receptor antagonists. PLoS One 2011; 6: e16406.
43. Steffey MA, Brosnan RJ, Steffey EP. Assessment of halothane and sevoflurane anesthesia in spontaneously breathing rats. Am J Vet Res 2003; 64: 470-474. (Pubitemid 36798590)
44. Gozzi A, Ceolin L, Schwarz A, Reese T, Bertani S, Bifone A. A multimodality investigation of cerebral haemodynamics and autoregulation in phMRI. Magn Reson Imaging 2007; 25: 826-833. (Pubitemid 47081368)
45. Zaharchuk G, Mandeville JB, Bogdanov AA Jr, Weissleder R, Rosen BR, Marota JJ. Cerebrovascular dynamics of autoregulation and hypoperfusion. An MRI study of CBF and changes in total and microvascular cerebral blood volume during hemorrhagic hypotension. Stroke 1999; 30: 2197-2204.
46. Zahm DS. Functional-anatomical implications of the nucleus accumbens core and shell subterritories. Ann N Y Acad Sci 1999; 877: 113-128. (Pubitemid 29351854)
47. Solinas M, Ferri S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 2002; 22: 6321-6324. (Pubitemid 35386385)
48. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182-217.
49. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000; 408: 199-203.
50. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 1996; 16: 1179-1188. (Pubitemid 26227239)
51. Snyder GL, Allen PB, Fienberg AA, Valle CG, Huganir RL, Nairn AC et al. Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J Neurosci 2000; 20: 4480-4488. (Pubitemid 30396613)
52. Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010; 13: 635-641.
53. De Mei C, Ramos M, Iitaka C, Borrelli E. Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol 2009; 9: 53-58.
54. Rouge-Pont F, Usiello A, Benoit-Marand M, Gonon F, Piazza PV, Borrelli E. Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors. J Neurosci 2002; 22: 3293-3301. (Pubitemid 35379217)
55. Hakansson K, Pozzi L, Usiello A, Haycock J, Borrelli E, Fisone G. Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. Eur J Neurosci 2004; 20: 1108-1112. (Pubitemid 39141317)
56. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P et al. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci USA 2003; 100: 4305-4309. (Pubitemid 36418198)
57. Hakansson K, Galdi S, Hendrick J, Snyder G, Greengard P, Fisone G. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem 2006; 96: 482-488.
58. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 2004; 44: 269-296. (Pubitemid 38263842)
59. Valjent E, Bertran-Gonzalez J, Bowling H, Lopez S, Santini E, Matamales M et al. Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32. Neuropsychopharmacology 2011; 36: 2561-2570.
60. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999; 22: 521-527. (Pubitemid 29481853)
61. Bolivar VJ, Walters SR, Phoenix JL. Assessing autism-like behavior in mice: variations in social interactions among inbred strains. Behav Brain Res 2007; 176: 21-26. (Pubitemid 44879629)
62. Moy SS, Nadler JJ, Poe MD, Nonneman RJ, Young NB, Koller BH et al. Development of a mouse test for repetitive, restricted behaviors: relevance to autism. Behav Brain Res 2008; 188: 178-194.
63. Scattoni ML, Gandhy SU, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in the BTBR T+tf/J mouse model of autism. PLoS One 2008; 3: e3067.
64. Wohr M, Roullet FI, Crawley JN. Reduced scent marking and ultrasonic vocalizations in the BTBR T+tf/J mouse model of autism. Genes Brain Behav 2011; 10: 35-43.
65. Yang M, Zhodzishsky V, Crawley JN. Social deficits in BTBR T + tf/J mice are unchanged by cross-fostering with C57BL/6J mothers. Int J Dev Neurosci 2007; 25: 515-521. (Pubitemid 350184243)
66. Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci 2010; 11: 490-502.
67. Robinson PD, Schutz CK, Macciardi F, White BN, Holden JJA. Genetically determined low maternal serum dopamine beta-hydroxylase levels and the etiology of autism spectrum disorders. Am J Med Genet 2001; 100: 30-36. (Pubitemid 32240651)
68. Hettinger JA, Liu X, Schwartz CE, Michaelis RC, Holden JJA. A DRD1 haplotype is associated with risk for autism spectrum disorders in male-only affected sib-pair families. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 628-636. (Pubitemid 351961666)
69. Staal WG, De Krom M, De Jonge MV. Brief report: the dopamine-3-receptor gene (DRD3) is associated with specific repetitive behavior in autism spectrum disorder (ASD). J Autism Dev Disord 2012; 42: 885-888.
70. Freitag C, Agelopoulos K, Huy E, Rothermundt M, Krakowitzky P, Meyer J et al. Adenosine A2A receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder. Eur Child Adolesc Psychiatry 2010; 19: 67-74.
71. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebocontrolled trial. J Autism Dev Disord 2007; 37: 367-373.
72. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124: 1533-1540.
73. Cervenka S, Hedman E, Ikoma Y, Djurfeldt DR, Ruck C, Halldin C et al. Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder. Transl Psychiatry 2012; 2: e120.
74. Schneier FR, Martinez D, Abi-Dargham A, Zea Ponce Y, Simpson HB, Liebowitz MR et al. Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety 2008; 25: 1-7. (Pubitemid 351213919)
75. Gingrich B, Liu Y, Cascio C, Wang Z, Insel TR. Dopamine D2 receptors in the nucleus accumbens are important for social attachment in female prairie voles (Microtus ochrogaster). Behav Neurosci 2000; 114: 173-183. (Pubitemid 30131596)
76. Peca J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011; 472: 437-442.
77. Rogers T, Dickson P, McKimm E, Heck D, Goldowitz D, Blaha C et al. Reorganization of circuits underlying cerebellar modulation of prefrontal cortical dopamine in mouse models of autism spectrum disorder. Cerebellum 2013; 12: 547-556.
78. Oddi D, Crusio WE, D'Amato FR, Pietropaolo S. Monogenic mouse models of social dysfunction: implications for autism. Behav Brain Res 2013; 251: 75-84.
79. Kao FC, Su SH, Carlson G, Liao W. MeCP2-mediated alterations of striatal features accompany psychomotor deficits in a mouse model of Rett syndrome. Brain Struct Funct 2013; 1-16.
80. Crawley JN. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 2007; 17: 448-459. (Pubitemid 47537604)
81. Badaruddin D, Andrews G, Bolte S, Schilmoeller K, Schilmoeller G, Paul L et al. Social and behavioral problems of children with agenesis of the corpus callosum. Child Psychiatry Hum Dev 2007; 38: 287-302. (Pubitemid 47583247)
82. Lau YC, Hinkley LB, Bukshpun P, Strominger ZA, Wakahiro ML, Baron-Cohen S et al. Autism traits in individuals with agenesis of the corpus callosum. J Autism Dev Disord 2012; 43: 1106-1118.
83. Sasaki M, Nakagawa E, Sugai K, Shimizu Y, Hattori A, Nonoda Y et al. Brain perfusion SPECT and EEG findings in children with autism spectrum disorders and medically intractable epilepsy. Brain Dev 2010; 32: 776-782.
84. Han S, Tai C, Jones C, Scheuer T, Catterall W. Enhancement of inhibitory neurotransmission by GABAA receptors ameliorates behavioral deficits in a mouse model of autism. Neuron 2014; 81: 1282-1289.
85. Gogolla N, LeBlanc J, Quast K, Sudhof T, Fagiolini M, Hensch T. Common circuit defect of excitatory-inhibitory balance in mouse models of autism. J Neurodevelop Disord 2009; 1: 172-181.
86. Zikopoulos B, Barbas H. Altered neural connectivity in excitatory and inhibitory cortical circuits in autism. Front Hum Neuroscience 2013; 7: 609.
87. Dichter GS, Felder JN, Green SR, Rittenberg AM, Sasson NJ, Bodfish JW. Reward circuitry function in autism spectrum disorders. Soc Cogn Affect Neurosci 2012; 7: 160-172.
88. McTighe SM, Neal SJ, Lin Q, Hughes ZA, Smith DG. The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex. PLoS One 2013; 8: e62189.
89. Pearson BL, Bettis JK, Meyza KZ, Yamamoto LY, Blanchard DC, Blanchard RJ. Absence of social conditioned place preference in BTBR T+tf/J mice: Relevance for social motivation testing in rodent models of autism. Behav Brain Res 2012; 233: 99-104.
90. Tordoff MG, Ellis HT. Taste dysfunction in BTBR mice due to a mutation of Itpr3, the inositol triphosphate receptor 3 gene. Physiol Genomics 2013; 45: 834-855.
91. Amodeo DA, Jones JH, Sweeney JA, Ragozzino ME. Differences in BTBR T+ tf/J and C57BL/6J mice on probabilistic reversal learning and stereotyped behaviors. Behav Brain Res 2012; 227: 64-72.
92. Klanker M, Feenstra M, Denys D. Dopaminergic control of cognitive flexibility in humans and animals. Front Neurosci 2013; 7: 201.
93. Sharma A, Shaw SR. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis. J Pediatr Health Care 2012; 26: 291-299.
94. Chadman KK. Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism. Pharmacol Biochem Behav 2011; 97: 586-594.
95. Chavez B, Chavez-Brown M, Rey JA. Role of risperidone in children with autism spectrum disorder. Ann Pharmacother 2006; 40: 909-916. (Pubitemid 43765008)
96. Gaspar P, Bloch B, Le Moine C. D1 and D2 receptor gene expression in the rat frontal cortex: cellular localization in different classes of efferent neurons. Eur J Neurosci 1995; 7: 1050-1063.
97. Floresco SB, Tse MT. Dopaminergic Regulation of Inhibitory and Excitatory Transmission in the Basolateral Amygdala-Prefrontal Cortical Pathway. J Neurosci 2007; 27: 2045-2057.
98. Khan ZU, Gutierrez A, Martin R, Pelafiel A, Rivera A, De La Calle A. Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. J Comp Neurol 1998; 402: 353-371 (Pubitemid 28541684)